GENE THERAPY AND ITS SUPPLY CHAINS ARE NOT WELL UNDERSTOOD

Why are they being rushed through?

WHAT ARE THE ISSUES?

On Aug. 30, 2017, the Food and Drug Administration (FDA) approved the first gene therapy product to launch in the U.S. Novartis’ drug—brand name Kymriah—is now out of the clinic and available to patients. Eye-watering price aside, it has been hailed as a landmark event in the history of the U.S. pharma industry.

The clinical trials le…